196 related articles for article (PubMed ID: 28958992)
21. Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma.
Li N; Maly DJ; Chanthery YH; Sirkis DW; Nakamura JL; Berger MS; James CD; Shokat KM; Weiss WA; Persson AI
Mol Cancer Ther; 2015 Feb; 14(2):419-28. PubMed ID: 25522764
[TBL] [Abstract][Full Text] [Related]
22. 5-iodo-2-pyrimidinone-2'-deoxyribose-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts.
Kinsella TJ; Kinsella MT; Seo Y; Berk G
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1254-61. PubMed ID: 17967315
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.
Eshleman JS; Carlson BL; Mladek AC; Kastner BD; Shide KL; Sarkaria JN
Cancer Res; 2002 Dec; 62(24):7291-7. PubMed ID: 12499272
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.
Riedel M; Struve N; Müller-Goebel J; Köcher S; Petersen C; Dikomey E; Rothkamm K; Kriegs M
Oncotarget; 2016 Sep; 7(38):61988-61995. PubMed ID: 27542273
[TBL] [Abstract][Full Text] [Related]
25. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
[TBL] [Abstract][Full Text] [Related]
26. The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.
Shannon AM; Telfer BA; Smith PD; Babur M; Logie A; Wilkinson RW; Debray C; Stratford IJ; Williams KJ; Wedge SR
Clin Cancer Res; 2009 Nov; 15(21):6619-29. PubMed ID: 19843666
[TBL] [Abstract][Full Text] [Related]
27. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR
Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082
[TBL] [Abstract][Full Text] [Related]
28. Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.
Maachani UB; Kramp T; Hanson R; Zhao S; Celiku O; Shankavaram U; Colombo R; Caplen NJ; Camphausen K; Tandle A
Mol Cancer Res; 2015 May; 13(5):852-62. PubMed ID: 25722303
[TBL] [Abstract][Full Text] [Related]
29. Novel chemical library screen identifies naturally occurring plant products that specifically disrupt glioblastoma-endothelial cell interactions.
Sengupta R; Barone A; Marasa J; Taylor S; Jackson E; Warrington NM; Rao S; Kim AH; Leonard JR; Piwnica-Worms D; Rubin JB
Oncotarget; 2015 Jul; 6(21):18282-92. PubMed ID: 26286961
[TBL] [Abstract][Full Text] [Related]
30. Radiation Drives the Evolution of Orthotopic Xenografts Initiated from Glioblastoma Stem-like Cells.
McAbee JH; Rath BH; Valdez K; Young DL; Wu X; Shankavaram UT; Camphausen K; Tofilon PJ
Cancer Res; 2019 Dec; 79(23):6032-6043. PubMed ID: 31615806
[TBL] [Abstract][Full Text] [Related]
31. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
32. Microenvironmental regulation of glioblastoma radioresponse.
Jamal M; Rath BH; Williams ES; Camphausen K; Tofilon PJ
Clin Cancer Res; 2010 Dec; 16(24):6049-59. PubMed ID: 21037023
[TBL] [Abstract][Full Text] [Related]
33. Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study.
Stegen B; Nieto A; Albrecht V; Maas J; Orth M; Neumaier K; Reinhardt S; Weick-Kleemann M; Goetz W; Reinhart M; Parodi K; Belka C; Niyazi M; Lauber K
Radiat Oncol; 2020 Jan; 15(1):19. PubMed ID: 31969174
[TBL] [Abstract][Full Text] [Related]
34. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
Wachsberger PR; Lawrence YR; Liu Y; Rice B; Feo N; Leiby B; Dicker AP
J Cancer Res Clin Oncol; 2014 Apr; 140(4):573-82. PubMed ID: 24500492
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG
Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
37. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.
Sarcar B; Kahali S; Prabhu AH; Shumway SD; Xu Y; Demuth T; Chinnaiyan P
Mol Cancer Ther; 2011 Dec; 10(12):2405-14. PubMed ID: 21992793
[TBL] [Abstract][Full Text] [Related]
38. Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.
Bouras A; Kaluzova M; Hadjipanayis CG
J Neurooncol; 2015 Aug; 124(1):13-22. PubMed ID: 25981803
[TBL] [Abstract][Full Text] [Related]
39. Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.
Kurokawa C; Geekiyanage H; Allen C; Iankov I; Schroeder M; Carlson B; Bakken K; Sarkaria J; Ecsedy JA; D'Assoro A; Friday B; Galanis E
J Neurooncol; 2017 Jan; 131(1):41-48. PubMed ID: 27816996
[TBL] [Abstract][Full Text] [Related]
40. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
